



ClearGuard™ HD

Antimicrobial Barrier Caps for Haemodialysis Catheters

Clinically proven to reduce the rate of bloodstream infections in haemodialysis catheters and recommended in the UK's National Institute for Health and Care Excellence (NICE) Medical Technologies Guidance [MTG62]

icumedical
human connections

Reduce haemodialysis catheter infections with clinically proven technology

Catheter infections are frequent, costly, and deadly


- › Increased infection rates are associated with use of invasive devices, in particular, central lines, urinary catheters, and ventilators.¹
- › Prevalence of catheter use has been around 14%, i.e. one in seven prevalent dialysis patients in Australia.²
- › Per the George Institute: In an average Australian Dialysis unit, dialysis catheters result in between 15 and 33 episodes of bacteraemia per year; 2 and 4 deaths per year and cost \$330k–\$770k per year.³



Reduce haemodialysis catheter infections by up to 63%⁴

The ClearGuard HD antimicrobial barrier cap is the first and only device for sale designed to kill infection-causing bacteria inside a haemodialysis catheter hub.* ClearGuard HD features a rod that extends into the haemodialysis catheter hub. The rod and cap threads are coated with chlorhexidine, a well-known broad-spectrum antimicrobial agent.

Antimicrobial agent remains in desired region due to the existing clamps



- › When the ClearGuard HD cap is inserted into a liquid-filled catheter, chlorhexidine elutes from the rod into the catheter lock solution
- › The chlorhexidine coating dissolves to kill microorganisms on the inside and outside of the catheter hub
- › The existing catheter clamp holds the antimicrobial agent inside the catheter hub between treatments
- › ClearGuard HD caps are used in place of a standard cap or connector


*Designed to kill microorganisms, not intended to be used for treatment of existing infections.

Clearguard HD antimicrobial barrier caps have been clinically proven to reduce CLABSI in haemodialysis catheter patients^{4,5}

Multiple large, prospective, cluster-randomised multicenter open-label trials demonstrated a significant reduction in the rate of positive blood cultures (PBCs) and CLABSIs using ClearGuard HD caps versus control groups.

JASN
Journal of the American Society of Nephrology

Cluster-Randomized Trial of Devices to Prevent Catheter-Related Bloodstream Infections



ClearGuard HD Caps vs. Tego™ + Curores™

Brunelli, SM et al. Cluster-randomized trial of devices to prevent catheter-related bloodstream infection. J Am Soc Nephrol 2018 Apr; 29(4):1336-1343.


- › 13-month prospective, cluster-randomised multicenter open-label trial
- › 1,671 patients (826 treatment, 845 control) accruing ~183,000 CVC days
- › 40 centers across the US
- › Primary endpoint was PBC rate as an indicator of BSI rate

Results: Use of the ClearGuard HD caps for 13 months was associated with a 63% lower BSI rate vs. use of Tego + Curores.

Curores is a trademark of 3M Company.

AJKD
AMERICAN JOURNAL OF KIDNEY DISEASES

Dialysis Catheter-Related Bloodstream Infections: A Cluster-Randomized Trial of the ClearGuard HD Antimicrobial Barrier Cap



ClearGuard HD Caps vs. Standard Dialysis Caps

Hymes, JL et al. Dialysis catheter-related bloodstream infections: A cluster-randomized trial of the ClearGuard HD antimicrobial barrier cap. Am J Kidney Dis. 2017; 69(2):220-227.

- › 12-month prospective, cluster-randomised, multicenter, open-label comparative effectiveness trial in haemodialysis patients with central venous catheters
- › 2,470 patients (1,245 treatment, 1,225 control) accruing ~350,000 CVC days
- › 40 centers across the US
- › Primary endpoint was PBC rate as an indicator of BSI rate

Results: Use of the ClearGuard HD caps for 12 months was associated with a 56% lower BSI rate vs. use of standard caps. When considering sustained use (defined as 6 months of the study), the intervention vs. control was associated with a 69% lower BSI rate.

ClearGuard HD antimicrobial barrier caps used by leading US hospitals and clinics

For years, dialysis staff at hospitals and clinics have focused on educational initiatives to reduce bloodstream infections in haemodialysis patients with limited impact. ClearGuard HD caps succeed in reducing infections by killing bacteria where bloodstream infections start-inside the haemodialysis catheter hub. With over 400 hospitals and over 3,700 outpatient dialysis clinics as customers, ClearGuard HD caps are becoming an increasingly important part of haemodialysis infection control best practices.



Recommended in the UK's NICE National Guidance for haemodialysis catheter-related bloodstream infections: 2021**

<https://www.nice.org.uk/guidance/mtg62/>



ClearGuard HD caps named in *Newsweek's* Best Infection Prevention Products two years in a row

These infection control products were evaluated using four criteria: effectiveness, safety (to both patient and healthcare worker), successful real-world implementation, and the stability of the company (to support future implementations).



National
Kidney
Foundation®

KDOQI®
Kidney Disease
Outcomes Quality Initiative

ClearGuard HD caps recommended in NKF's KDOQI Clinical Practice Guideline for Vascular Access: 2019⁶

21.3 KDOQI considers it reasonable to use an antimicrobial barrier cap to help reduce CRBSI in high-risk patients or facilities; the choice of connector should be based on clinician's discretion and best clinical judgment. (Expert Opinion)

Product Ordering information

Product Code	Case Quantity	Product Description
011-CGHD-100	100	ClearGuard™ HD Caps (1 Red, 1 Blue)



Contact us today to find out how ClearGuard HD can play a large role in your infection control practices. Visit www.icumed.com or call 1300 428 652 for Australia, 0800 629 637 for New Zealand.

¹ Report on the Burden of Endemic Health Care-Associated Infection Worldwide, World Health Organization, 2011.

² University of Sydney School of Public Health, Faculty of Health and Medicine, 2022, CARi GUIDELINES, accessed 28 September 2022, <<https://www.cariguideelines.org/>>.

³ The George Institute, 2022, The George Institute for Global Health, accessed 28 September 2022, <<https://www.georgeinstitute.org/>>.

⁴ Brunelli, SM et al. Cluster-randomized trial of devices to prevent catheter-related bloodstream infection. J Am Soc Nephrol. 2018 Apr;29(4):1336-1343.

⁵ Hymes, JL et al. Dialysis catheter-related bloodstream infections: a cluster-randomized trial of the ClearGuard HD antimicrobial barrier cap. Am J Kidney Dis. 2017 Feb;69(2):220-227.

⁶ Lok CE, Huber TS, Lee T, et al; KDOQI Vascular Access Guideline Work Group. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis. 2020;75(4)(suppl 2):S1-S164.

**© NICE 2021 ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections. Medical technologies guidance [MTG62]. Available from <https://www.nice.org.uk/guidance/mtg62/chapter/1-Recommendations> All rights reserved. Subject to Notice of rights NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.